親愛的疫苗研究者、專家和行業領袖，我們懷著極大的興奮之情，誠摯地邀請您參加即將在2024年3月于上海舉辦的Vaccine Innovation Forum（VIF） World 2024（第5屆疫苗創新國際論壇）。這將是全球疫苗領域最引人矚目的盛會之一，匯聚了來自世界各地的疫苗開發和免疫領域的頂尖專家、研究人員、政策制定者和產業領袖。
 

會議主題："疫苗的未來：推動全球健康"

學術顧問委員會：
Bin Wang, CSO, Advaccine/Professor, Fudan University, China
David Weiner, Executive Vice President, Wistar Institute; Professor Emeritus, University of Pennsylvania, USA
Chunlin Xin, Vice President, Cansino Biologics, China
Yuanqing Liu, CSO, Immorna China, China
Heinrich Haas, Former VP, Formulation& Drug delivery, BioNtech, Germany
Alain Bouckenooghe, CSO, Hilleman Laboratories, Singapore
Shaowei Li, Professor, Xiamen University, China
Sergey Arakelov, Sci. Dir., St. Petersburg Scientific Research Institute of Vaccines and Sera of the FMBA of Russia
Kiat Ruxrungtham, Director of Chula VRC, Chulalongkorn University,Thailand
Dexiang Chen, Chairman& General Manager, Maxvax Biology, China
Anna Du, Senior Program Officer, China Country Office, Bill & Melinda Gates Foundation, China
Li Shi, Board Chairman, Immune-Path Bio,China
Sean Du, Head, External R&D Asia Pacific, Global R&D, Sanofi Pasteur, China
Yuan Yuan, China Country Representative, Business & Alliance Management Lead, PATH, China
Petro Terblanche, CEO, Afrigen Biologics, South Africa

為什么參加：
前沿見解：發掘最新的疫苗研究發現、突破性技術和發展策略。
全球影響：為全球公共衛生作出貢獻，提高全球免疫水平。
大流行準備：從過去的疫情中汲取經驗教訓，探討通過創新疫苗開發來增強全球準備。
平等獲取：強調所有人群對疫苗的平等獲取的重要性，解決不平等問題。
中國的貢獻：探討中國在疫苗研究和生產方面的重要進展。

關鍵議題：
創新疫苗開發進展
新疫苗平臺和技術
基于RNA技術的疫苗及療法
動物疫苗
癌癥疫苗與免疫療法
生物工藝和制造
臨床試驗與疫苗安全性
市場準入、監管和國際合作
佐劑、制劑和遞送技術

早期確認演講嘉賓：
George Siber, President, Siber Biotechnologies LLC, USA
Rajinder Suri, CEO, DCVMN International, India
Petro Terblanche, CEO, Afrigen Biologics, South Africa
Simon Graham, Professor, The Pirbright Institute, UK
Kar Muthumani, CSO, GeneOne Life Science, USA
Shan Lu, Professor, University of Massachusetts Medical School, USA
Joon Haeng Rhee, Professor, Chonnam National University Medical School, South Korea
Nikolai Petrovsky, Founder, Vaxine, Australia
Hun Kim, President of Global R&BD, SK Bioscience, South Korea
Dal-Hee Min, CTO, Lemonex, South Korea
Kate Antrobus, Chief Investment Officer, Univercells, Belgium
Kiat Ruxrungtham, Director of Chula Vaccine Research Center, Chulalongkorn University, Thailand
Bin Wang, CSO, Advaccine/Professor, Fudan University, China
David Weiner, Executive Vice President, Wistar Institute; Professor Emeritus, University of Pennsylvania, USA
Andrew Wong, BD Director, Walvax/ General Manager, Shanghai Wotai Biotechnology, China
Nicaise Ndembi, Chief Science Advisor, Africa Centres for Disease Control and Prevention, Ethiopia
Jeffrey Ulmer, President, TechImmune, USA
Jicui Dong, Head, Local Production and Assistance Unit Regulation & PQ, Access to Medicines and Health Products Division,WHO, Switzerland
Ramesh Matur, Sr VP, Head R&D, Biological E, India
Kutub Mahmood, Scientific Director at PATH, USA
Ed Lavelle, Professor, Trinity College Dublin, Ireland
Mahesh Kumar, Senior Vice President, Global Biologics R&D, Zoetis, USA
Abdul Muktadir, Chairman and Managing Director, Incepta Pharmaceuticals/ Incepta Vaccine, Bangladesh
Francesco Berlanda Scorza,VP R&D, Global Health R&D Vaccines Head and GVGH Institute, GSK, Belgium
Baoming Jiang, Senior Scientist, Division of Viral Diseases- CDC, USA
James Wai Kuo Shih, Senior Advisor, Xiamen Innovax Biotech, ChinaHaibo Li, Professor, Army Medical University, China
Ken Ishii, Director, International Vaccine Design Center, Professor, University of Tokyo, Japan
Yu-shen Hsu, Chairman/Acting President, Advagene, Taiwan, China
Frank Chang, CSO, Reber Genetics, Taiwan, China
Shibo Jiang, Professor, Fudan University, China
Zoltan Kis, Lecturer, University of Sheffield, UK
Jeff Zhu, CEO, Reinovax Biologics, China
Michel De Wilde, Owner, MDW Consultant,LLC, Former SVP of R&D, Sanofi Pasteur, USA
Zhizheng Hu, Associate Director, RA, MSD
持續更新中
 
演講、贊助、參展、墻報及會議詳情，請掃碼：